

Quality Assurance Improves Accuracy of MRI Prostate Detection in a Community Based Setting

MP66-12

Christine Liaw, MD

Department of Urology
Icahn School of Medicine at Mount
Sinai, New York

and Steven A Kaplan, Ardeshir Rastineha, Carl A
Olsson, Kathleen Latino, Deepak A Kapoor



**Mount
Sinai**

Quality Assurance Improves Accuracy of MRI Prostate Detection in a Community Based Setting

- Aim: To determine if a standardized quality assurance process could impact results of mpMRI fusion prostate biopsies
- Methods
 - fusion biopsy of 5/103 providers at IMP
 - QA process: urologists and radiologists required to cross-reference biopsy results to all MRI reads
 - data: positive biopsy rates for PI-RADS 4 and 5 lesions, negative rates for PI-RADS 3

Quality Assurance Improves Accuracy of MRI Prostate Detection in a Community Based Setting

Year	All P4/5		P4/5 Primary Target	
	QA	Non-QA	QA	Non-QA
2014	45.5%	36.4%	45.5%	37.5%
2015	51.5%	40.0%	51.6%	44.4%
2016	53.3%	46.1%	54.4%	48.4%
2017	64.6%	43.9%	64.2%	47.6%
2018	66.3%	53.2%	67.5%	44.5%

Institution of a standardized, ongoing review QA process correlating histopathological findings with radiological interpretation of mpMRI findings improves biopsy accuracy more rapidly and to greater degree, particularly for lesions identified as the the primary biopsy target. These programs should be considered by all providers performing this procedure.